The COMPASs Study: Community Preferences for Prostate cAncer Screening. Protocol for a quantitative preference study - Abstract

Background: Prostate cancer screening using prostate-specific antigen (PSA) testing remains controversial. Trade-offs between the potential benefits and downsides of screening must be weighed by men deciding whether to participate in prostate cancer screening; little is known about benefit:harm trade-offs men are willing to accept.

Methods/Design: The Community Preferences for Prostate Cancer Screening (COMPASs) Study examines Australian men's preferences for prostate cancer screening using PSA testing. The aims are to (1) determine which factors influence men's decision to participate in prostate cancer screening or not and (2) determine the extent of trade-offs between benefits and harms that men are willing to accept in making these decisions. Quantitative methods will be used to assess men's preferences for PSA screening. Using data on the quantitative outcomes of PSA testing from the published literature, a discrete choice study will be designed to quantitatively assess men's preferences. A web-based survey will be conducted in approximately 1000 community respondents aged 40-69 years, stratified by family history of prostate cancer, to assess men's preferences for PSA testing. A mixed logit model will be used; model results will be expressed as parameter estimates (β) and the odds of choosing screening over no screening. Trade-offs between attributes will also be calculated.

Ethics and Dissemination: The COMPASs study has been approved by the University of Sydney, Human Research Ethics committee (Protocol number 13186). The results will be published in internal reports, in peer-reviewed scientific journals as well as via conference presentations.

Written by:
Howard K, Salkeld GP, Mann GJ, Patel MI, Cunich M, Pignone MP.   Are you the author?
School of Public Health, University of Sydney, Sydney, New South Wales, Australia.

Reference: BMJ Open. 2012 Jan 7;2(1):e000587. Print 2012.
doi: 10.1136/bmjopen-2011-000587

PubMed Abstract
PMID: 22226686 Prostate Cancer Section